NeuroOne Medical Technologies (NASDAQ:NMTC) Trading 0.6% Higher – Here’s What Happened

Posted by Francis Steltz on Jun 9th, 2026

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC – Get Free Report) rose 0.6% during mid-day trading on Monday . The company traded as high as $3.53 and last traded at $3.46. Approximately 35,919 shares were traded during mid-day trading, an increase of 6% from the average daily volume of 33,939 shares. The stock had previously closed at $3.44.

Wall Street Analyst Weigh In

NMTC has been the topic of a number of recent research reports. JonesTrading initiated coverage on shares of NeuroOne Medical Technologies in a report on Monday, March 2nd. They issued a “buy” rating and a $9.00 target price on the stock. LADENBURG THALM/SH SH raised their target price on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Zacks Research cut shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, March 13th. Wall Street Zen raised shares of NeuroOne Medical Technologies to a “sell” rating in a report on Saturday, February 21st. Finally, Weiss Ratings lowered shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $11.67.

Get Our Latest Stock Analysis on NMTC

NeuroOne Medical Technologies Stock Up 0.6%

The firm has a market cap of $29.83 million, a price-to-earnings ratio of -4.07 and a beta of 0.51. The stock’s 50 day moving average is $4.27 and its 200 day moving average is $4.48.

NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The business had revenue of $2.39 million for the quarter, compared to the consensus estimate of $2.58 million. NeuroOne Medical Technologies had a negative return on equity of 98.33% and a negative net margin of 68.35%. Analysts anticipate that NeuroOne Medical Technologies Corporation will post -0.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NeuroOne Medical Technologies

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of NeuroOne Medical Technologies by 31.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after purchasing an additional 375,639 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of NeuroOne Medical Technologies in the 4th quarter valued at $143,000. Virtu Financial LLC acquired a new stake in shares of NeuroOne Medical Technologies in the 3rd quarter valued at $88,000. Goldman Sachs Group Inc. acquired a new stake in shares of NeuroOne Medical Technologies in the 1st quarter valued at $84,000. Finally, XTX Topco Ltd acquired a new stake in shares of NeuroOne Medical Technologies in the 2nd quarter valued at $51,000. Institutional investors and hedge funds own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

(Get Free Report)

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.